Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum MIF in Acute Kidney Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02352506
Recruitment Status : Active, not recruiting
First Posted : February 2, 2015
Last Update Posted : November 22, 2019
Sponsor:
Information provided by (Responsible Party):
David M Baron, MD, Medical University of Vienna

Brief Summary:
Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

Condition or disease Intervention/treatment
Acute Kidney Injury Other: Blood draw for measurement of MIF

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Macrophage Migration Inhibitory Factor in the Serum of Critically Ill Patients as an Early Marker for Acute Kidney Injury
Study Start Date : January 2015
Actual Primary Completion Date : November 2019
Estimated Study Completion Date : December 2020

Group/Cohort Intervention/treatment
AKI
Patients developing AKI during the ICU stay
Other: Blood draw for measurement of MIF
Observational study, no intervention

No AKI
Matched controls not developing AKI during the ICU stay
Other: Blood draw for measurement of MIF
Observational study, no intervention




Primary Outcome Measures :
  1. Macrophage migration inhibitory factor [ Time Frame: Up to 14 days ]

Secondary Outcome Measures :
  1. Serum creatinine [ Time Frame: Up to 14 days ]

Biospecimen Retention:   Samples Without DNA
Serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Critical care patients
Criteria

Exclusion Criteria:

  • Age < 18 years and > 80 years
  • Patients with chronic dialysis
  • Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study
  • Patients with an expected length of ICU stay shorter than 3 days
  • Patients with a low probability of surviving the first 2 days after ICU admission
  • Pregnancy and nursing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02352506


Locations
Layout table for location information
Austria
Medical University of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Layout table for additonal information
Responsible Party: David M Baron, MD, Univ.-Ass., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT02352506    
Other Study ID Numbers: 1680/2014
First Posted: February 2, 2015    Key Record Dates
Last Update Posted: November 22, 2019
Last Verified: November 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Wounds and Injuries
Renal Insufficiency
Kidney Diseases
Urologic Diseases